Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus
New York, Jan 9, 2026, 20:01 (EST) — Market closed. Merck & Co (MRK.N) shares slipped on Friday following reports that the pharma giant is in talks to acquire cancer-focused biotech Revolution Medicines (RVMD.O) for as much as $32 billion. Merck ended the day down 0.4% at $110.53, after swinging between $110.26 and $112.46. (Reuters) The possible bid comes as…